MEDIA RELEASE
23 NOVEMBER 2020

SENIOR CAR T EXECUTIVES JENNIFER CHOW (ex KITE) & DR SYED RIZVI (ex LEGEND) JOIN CHIMERIC LEADERSHIP TEAM

HIGHLIGHTS

- Joining as COO, Ms Chow comes to Chimeric Therapeutics from Kite Pharma where she was the Head, Global Marketing, Analytics and Commercial Operations responsible for ensuring that the development of Kite's assets and commercial operations were optimised to maximise their global value
- Ms Chow has more than 20 years of strategic and operational experience in the biotechnology and pharmaceutical sector, working within commercialisation teams across clinical development, regulatory, medical and technical operations in major global markets
- Joining as CMO, Dr Rizvi specialises in CAR T drug development with more than 20 years experience in pharma, taking drugs through regulatory approvals and commercial launches
- Dr Rizvi played a key role in the US$450m IPO of Legend Biotech (NASDAQ:LEGN, $4b market cap), the second largest biotech IPO ever and the largest US biotech IPO of 2020
- Legend Biotech has taken its Cilta-cel (JNJ4528) CAR-T asset from proof of concept in 2017 to BLA submission in 2020, followed by likely approval in 2021
- Ms Chow & Dr Rizvi bring extensive experience optimising the development of CAR T therapies for global commercialisation and will be key in the development of Chimeric's CLTX-CAR T technology

Chimeric Therapeutics ("Chimeric" of the "Company"), a drug development company focused on novel CAR T therapies for solid tumors, is pleased to announce the appointment of US-based executives Ms Jennifer Chow as Chief Operating Officer (COO) and Dr Syed Rizvi as Chief Medical Officer (CMO).

Ms Chow joins from Kite Pharmaceuticals, a cancer immunotherapy company with a primary focus on CAR T therapies, where she was Head of Global Marketing, Analytics and Commercial Operations. Within this role Ms Chow was responsible for assessing and prioritising research and external assets for development, ensuring optimal clinical development of the Kite pipeline for global commercialisation and differentiating the commercial operations customer experience to be industry leading. Kite Pharmaceuticals was acquired by Gilead Sciences as a subsidiary in 2017 for $11.9 billion.

Prior to joining Kite, Ms Chow was Global Cell Therapy Commercial Lead at Celgene Corporation, a pharmaceutical company specialising in cancer and immunology drugs, where she pioneered the design and development of its global CAR T commercial strategy and operating model.

Ms Chow also developed the global Celgene cell therapy customer experience model, and provided critical organisational insight into the novel operating costs associated with cell therapy. Celgene attracted widespread commercial interest for its work in the CAR T space, culminating in its US$74b+ acquisition by Bristol-Myers Squibb.

Dr Rizvi joins Chimeric from Legend Biotech (Legend), a global clinical-stage, NASDAQ listed biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications.

Dr Rizvi served as Vice President of Clinical Development, Medical Affairs & Clinical Sciences at Legend, where he led global co-development activities for Cilta-cel (JNJ4528), a B cell maturation antigen (BCMA)-directed CAR-T cell therapy.

Legend recently listed on NASDAQ after a US$450m IPO, the largest biotech IPO in the US for 2020. Dr Rizvi played an integral role in the IPO process, leading presentations and clinical discussions at roadshow meetings.

Legend's Cilta-cel (JNJ4528) asset is expected to achieve FDA approval as early as 2021, following a rapid product development process that began with proof of concept in 2017.

Dr Rizvi was formerly the Global Medical Affairs Head of Celgene Corporation's CAR-T Program, where he was responsible for the global medical strategy for Celgene's CAR-T assets, bb2121 in myeloma and lisocel (JCAR017) in lymphoma, leading multiple initiatives for the success of these therapies. Prior to Celgene, Dr Rizvi held global clinical leadership roles in oncology programs at Novartis Oncology, Merck & Company (MSD) & Genta Inc. (an oncology biotech). In addition, he also worked at Saint Vincent's Comprehensive Cancer Center, New York.

Chimeric's Executive Chairman Paul Hopper said: "It is a huge win for Chimeric to attract executives the quality of Jennifer and Syed, and we're excited to be able to announce these appointments to the management team. Each of them bring a wealth of experience in the successful global commercialisation of CAR T technologies with major players in the CAR T space, and this expertise will be vital in the development of our CLTX-CAR T asset and the Chimeric story as a whole."

Chimeric's CLTX-CAR T therapy, which uses a peptide derived from scorpion toxin to direct T cells to target glioblastoma (GBM), is currently being used in a Phase 1 clinical trial at City of Hope to treat GBM where dosing of patients is underway.

ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics is developing ground-breaking CAR-T cell therapies for solid tumors based on scientific research conducted by leading US CAR-T experts at the City of Hope (COH) Cancer Centre in Los Angeles. Its CLTX-CAR T technology incorporates chlorotoxin (CLTX), a peptide derived from scorpion toxin, as a novel CAR tumor recognition domain. This domain extends the range of CAR-T cell targeting in solid tumors.

Potent antitumor activity against glioblastoma (GBM) has been established in preclinical models. Currently undergoing Phase 1 clinical trials in GBM at COH, CLTX CAR-T has significant drug administration benefits since it can be delivered during an outpatient visit.

CLTX CAR-T cells differ from other GBM-targeting immunotherapies by its specific and broad recognition of patient tumors and of the majority of cells within these tumors. CLTX CAR-T cells target GBM through recognition of a receptor complex composed of membrane-bound matrix metalloprotease 2 (MMP2) and involving the chloride channel CLC3.

CLTX CAR-T cells do not exhibit off-tumor recognition of normal human or murine cells/tissues in preclinical models, consistent with the documented safety of administering other CLTX-containing therapeutic agents in humans.

The CLTX peptide has also demonstrated safety and specificity in clinical testing as a radiotherapy delivery conjugate and as an imaging agent in fluorescence-guided surgery for recurrent/refractory GBM.

CONTACT

Paul Hopper
Executive Chairman
P: +61 406 671 515
E: paulhopper@lifescienceportfolio.com
W: www.chimerictherapeutics.com